Atrial natriuretic factor (ANF), a biologically active peptide produced mainly in cardiomyocytes, is released into the circulation in response to atrial distension secondary to an increase in central blood volume and/or atrial pressure (1) (2) . In vivo and in vitro studies have shown that ANF can relax vascular smooth muscle, enhance excretion of sodium and water, inhibit the renin aldosterone system and antagonise the vasoconstrictor actions of angiotensin II and norepinephrine (3) (4) (5) . This spectrum of activity has lead to suggestions that ANF may be an important element in the homeostatic regulation of extracellular fluid volume and blood pressure (6) (7) .
In exploring regulatory mechanisms and responses of the ANF system in disease states associated with abnormal control of extracellular body fluids, renal failure has become an interesting area of focus. Patients with end-stage renal disease on chronic dialysis cannot maintain body fluid balance and extracellular fluid volume varies cyclically, gradually increasing during the interdialysis interval and decreasing rapidly during hemodialysis, often in association with impaired blood pressure control. Suggestions that release of ANF under these circumstances may represent a cardiac response to changes in preload and afterload, has lead to speculation on the existence of a link between plasma ANF levels and blood pressure in hypervolemia-prone uremic patients and to controversy concerning the potential physiological or pathological significance of the ANF system under these conditions. Seen in this context, ANF has been considered by some as a uremic toxin contributing to hypotension and hemodynamic instability following dialysis (8) , yet viewed by others as a potentially beneficial agent limiting production or activity of several compounds which may otherwise exacerbate sodium retention and hasten the development of hypertension (9) (10) (11) (12) (13) .
In an attempt to resolve these differing opinions approximately nineteen papers, primarily concerned with the investigation of plasma irANF levels before and after dialysis in end-stage renal patients, have appeared over the last three years (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . A brief summary of these data is presented in Table I .
The main aims of these studies have been to establish how and to what extent circulating irANF levels are altered during end stage renal disease and hemodialysis and to clarify whether such changes primarily reflect an appropriate response by the heart to variations in intravascular fluid load or whether other mechanisms are also involved.
As shown in Table I there is consensus among all investigators that plasma irANF levels are increased prior to, and decrease to a greater or lesser extent following, either hemodialysis or ultrafiltration. In 45% of the studies, hemodialysis restored irANF levels to essentially normal values (9-13, 18-20, 23) . These data clearly implicated fluid overload as the major factor responsible for elevated predialysis levels and suggested the potential usefulness of plasma irANP measurements as an index of volume expansion (10, 18) .
In contrasting reports, however, an inability to detect correlations with changes in weight or hematocrit (16, 26) and, in particular, the occurrence of residually high plasma levels of irANF after dialysis compared to what were considered normal values (8, 15, 16, 26) , prompted suggestions that factors other than simple volume expansion may determine pre and post dialysis plasma irANF levels and questioned the physiological significance and diagnostic value of changes in irANP under these conditions. Since ANF has vasorelaxant properties it was suggested that elevated levels found in some patients after dialysis could in theory have a detrimental effect on hemodynamic stability (8) . Furthermore, reductions in the rate of degradation and renal clearance have been proposed as additional plausible mechanisms which could ostensibly influence levels of irANF pre and post dialysis (27) .
At first sight, these suggestions may appear to necessitate a re-evaluation of initial ideas concerning underlying mechanisms, role and significance of changes in plasma irANF in end-stage renal disease; closer examination of the available data, however, provides little supportive evidence. In virtually all cases these conflicting views and apparently anomalous findings may be explained by the fact that additional complicating factors and aspects of methodology, which have an important influence on the measurement of circulating irANF levels, have in many cases not been adequately considered or controlled.
These factors include the likely simultaneous presence in several studies of undetected cardiac disease (17) (18) (19) 27) and/or peripheral neuropathy (8) , both of which may independently influence irANF levels. Differences in assay techniques also contribute to the widely varying measurements of irANF-like material (11, 20) . Apart from variable non-specific interference in plasma from different patients, particularly when using direct assays, the lack of identification in many cases of the material being detected may place additional limitations on interpretation since it is often unclear exactly what is being measured (11, 20, 23, 28) . Other factors such as the site of blood sampling may further complicate interpretation (20) since average values of irANF are some 22% higher in AV-fistula than peripheral venous blood (9) . Furthermore, dialysis-fluid composition may affect the degree of intravascular volume reduction (24, 29) , raising the possibility that in certain cases euvolemia was not achieved following dialysis (17) . Other influences include possible effects of medication on plasma levels or measurements of irANF-like material and, probably most importantly, the effect of age (9, 30, 31) and a lack, in many studies, of suitably matched normal controls. Considering these criteria it is apparent that, apart from renal failure per se, many other factors can affect the measurement of plasma irANF. The major body of evidence, however, clearly indicates that when the influence of these additional components can be excluded, pre and post dialysis irANF levels in uncomplicated end stage renal patients relate primarily to indices of fluid volume overload. This view is supported by our own studies of circulating irANF levels before and after dialysis in a group of 42 closely age-matched patients without cardiac disease who had been withdrawn from antihypertensive treatment two weeks prior to the studies (9). HPLC analysis of the material measured in the radioimmunoassay shows that this was either identical or very closely related to alpha-hANF and the major peak of immunoreactive material eluted at the position corresponding to synthetic ANF (Fig. 1) .
Plasma levels before dialysis were increased and decreased essentially to normal values found in healthy subjects of similar age after removal of excess fluid by dialysis (Fig. 2) .
This reinforces the view that atrial distension secondary to overhydration and/or increased systemic blood pressure and afterload is the primary cause of elevated plasma irANF in these patients. Additional data support this suggestion.
In the absence of renal failure, plasma irANF in patients with cardiac disease correlated positively with right atrial pressure and or pulmonary capillary wedge pressure (32, 33) . In hemodialysis patients these pressures have been shown to be closely related to the state of hydration (34) and were found in the present study to correlate closely with predialysis levels of plasma irANF in right atria, pulmonary artery and AV-fistula. The overriding importance of fluid status in regulating plasma irANF is further supported by positive correlations between ultrafiltration-induced decreases in body weight and associated changes in pulmonary arterial, arteriovenous-fistula, and venous plasma irANF and by the inverse association between hemodialysis induced changes in plasma irANF and hematocrit (Tab. II). Other studies have shown irANF levels in end stage renal failure to correlate with plasma volume (13) and left atrial diameter (35) . In addition, removal by ultrafiltration and subsequent reinfusion of 2 litres of saline in dialysis patients produced appropriate proportional changes in plasma irANF levels (17) . Isovolemic hemodialysis on the other hand failed to alter irANF levels (18, 36) . These studies clearly suggest that expansion of the extra- a estimated dry body weight, 70 ± 5 kg b P < 0.05 c P < 0.01 d P < 0.001 vs before dialysis cellular space and subsequently plasma volume is the main stimulus for secretion of ANF through effects on atrial stretch or filling pressure. Other factors which have been considered as contributory mechanisms responsible for changes in pre and post dialysis plasma irANF levels such as a decrease in degredation (13, 16, 27) , changes in clearance (8, 12, 15, 20) and/or removal of the peptide across the dialyser (13) are likely to be insignificant. Whether the half life of ANF (in normal subjects 3.2 min). (37) , is altered in renal failure is presently unknown but the rapid decrease in plasma irANF levels in response to fluid removal, particularly during ultrafiltration where the uremic millieu remains unaltered, would not support such a view (12, 13) . Similarly, alterations in renal clearance mechanisms (12, 27) are unlikely to contribute significantly to the increased pre-dialysis levels (normal total clearance 2.4 I/min) (38) . During its passage through the human kidneys, about 50% of endogenous irANF disappears from plasma (4) . Assuming a renal plasma flow of 600 ml/min/1.73 m 2 , no more than 12% of the total plasma clearance in man can be attributed to renal mechanisms. A total loss of excretory and metabolic capacity would, therefore, contribute minimally to the increases in plasma irANF found in end stage renal disease. Although in the present study a fraction of the plasma irANF was found to be removed across the hemodialysers or hemofilters this averaged only 25 or 50 ml/min respectively and was constant throughout the treatment session ( Fig. 3) . In comparison to the total clearance of irANF in normal man (2.4 I/min) such clearance could maximally contribute only 2% to the dialysis-induced decreases in circulating irANF. Unchanged plasma levels after isovolemic hemodialysis support this view (36) .
Whether blood pressure per se may also influence plasma irANF levels is still unclear. In several studies irANF levels correlated with blood pressure before and after dialysis. In the present study the tendancy for systolic BP to correlate with irANF levels reached statistical significance only after dialysis. Subgroup analysis of hypertensive versus normotensive patients showed a greater hemodialysis-induced BP reduction in hypertensives accompanied by a parallel tendancy for a more pronounced fall in irANF levels despite a similar volume contraction in the two groups as reflected by the increase in hematocrit (Fig. 4 ). This, however could simply reflect differences in pre-dialysis volume expansion in the two groups and greater effectiveness of the same relative volume reduction on BP and irANF. At present, the question remains unresolved.
Although the precise physiological consequences of increased plasma irANF in end stage renal disease have not been defined, levels comparable to those in hemodialysis patients produce a wide range of effects which, in addition to diuresis, include an acute BP reduction, fluid volume shift from the blood space to the extravascular compartment, a probable baroreflex activation of the sympathetic nervous system, inhibition of aldosterone and an acute increase in glomerular filtration (3) (4) (5) (6) . Similar effects have been reported following infusions of high doses of ANF in hemodialysis patients both before and after hemodialysis (39 o levels before dialysis and their return towards equivalent control values then appear as a normal response of this system to alleviation of the volume excess. Increased levels during volume overload may help to limit the development of hypertension by counteracting several of the contributory factors involved in its pathophysiology. ACKNOWLEDGEMENTS physiological volumetric regulatory mechanism and response to ANF secretion in uremic patients, suggesting that such activation may instigate a physiological response and serve as a purposeful compensatory mechanism to counteract norepinephrine and angiotensin-II mediated arteriolar vasoconstriction, antagonise aldosterone secretion and promote natriuresis thereby counteracting, at least partly, mechanisms of increased pre and afterloads in such patients. At present there is little evidence to support the suggestion that ANF may have detrimental consequences in uremia. Against this background, the majority of the evidence points to an effect of ANF in keeping with its proposed role as a hormone whose role is to regulate intravascular and cardiac volume homeostasis. Elevated This work was supported by the Swiss National Science Foundation. 
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